Alembic Pharma gets FDA approval for Solifenacin Succinate tablets
Category: #healthcare  By Akshay Kedari  Date: 2019-05-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Alembic Pharma gets FDA approval for Solifenacin Succinate tablets
  • The FDA approval was awarded to Solifenacin Succinate tablets’ abbreviated new drug application (ANDA).
  • The pharmaceutical firm now holds a total of 94 ANDA approvals from the US health regulator.

Alembic Pharmaceuticals Ltd., (Alembic Pharma), a renowned Indian multinational pharmaceutical firm, has reportedly announced that its overactive bladder treatment tablets, Solifenacin Succinate, have received approval from the United States Food and Drug Administration (USFDA).

Reports cite, the approved drug is a biosimilar that is therapeutically equivalent to Vesicare tablets, a reference listed drug developed by the U.S. arm of Japanese pharmaceutical firm, Astellas Pharma Inc. (Astellas).

According to a press release by Alembic Pharma, similar to Vesicare, the Solifenacin Succinate tablets would be made available to customer in two doses, 5 mg and 10 mg. The tablets are muscarinic antagonist that are indicated for the treatment of an overactive bladder that shows symptoms of urgency, urge urinary incontinence as well as urinary frequency.

Quoting sales data from reliable sources, the company stated that the Solifenacin Succinate tablets, both in doses of 5 mg and 10 mg boast of a market size that is estimated to be approximately $967 million for a period of 12 months which ended in December 2018.

The pharmaceutical firm now reportedly holds a total of 94 ANDA approvals from the US health regulator. Alembic Pharmaceuticals’ shares were trading at approximately INR 533.40 each, up by approximately 0.77% on the Bombay Stock Exchange (BSE) following the drug’s approval.

About Alembic Pharmaceuticals:

Alembic Pharmaceuticals Ltd. is a vertically integrated research & development pharmaceutical firm and has been a prominent player in the healthcare sector since 1907. The company is publicly listed and is especially known for manufacturing & marketing generic pharmaceutical products throughout the world. The firm boasts of its state-of-the-art research & development (R&D) facilities that have been approved by the regulatory authorities of several developed nations, which also includes the United States FDA.

Source Credit:

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-overactive-bladder-treatment-drug/articleshow/69423547.cms

https://www.alembicpharmaceuticals.com/wp-content/uploads/2019/05/Press-Release-USFDA-Approval-Solifenacin-Succinate-Tablets-May-2019.pdf

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

CoreMap Announces Completion of $10.5 Million Series A Financing
CoreMap Announces Completion of $10.5 Million Series A Financing
By Akshay Kedari

CoreMap announced that it has accomplished $10.5 million Series A financing which was led by Qure Ve...

Spain to conduct first trial of Johnson & Johnson’s COVID-19 vaccine
Spain to conduct first trial of Johnson & Johnson’s COVID-19 vaccine
By Akshay Kedari

According to reliable sources, Spain is planning to host the phase 2 clinical trials of the US-based...

Fulcrum Biometrics acquires DelaneyBiometrics, adds European footprint
Fulcrum Biometrics acquires DelaneyBiometrics, adds European footprint
By Akshay Kedari

Fulcrum Biometrics, Inc. has announced a strategic acquisition of Delaney Secure Ltd., a UK-based bi...